In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

Qiu N. Sun, Annette W. Fothergill, Dora I. McCarthy, Michael G. Rinaldi, John R. Graybill

Research output: Contribution to journalArticle

273 Scopus citations

Abstract

In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.

Original languageEnglish (US)
Pages (from-to)1581-1582
Number of pages2
JournalAntimicrobial agents and chemotherapy
Volume46
Issue number5
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes'. Together they form a unique fingerprint.

  • Cite this